1
|
Rao F, Lyu T, Feng Z, Wu Y, Ni Y, Zhu W. A landmark-supervised registration framework for multi-phase CT images with cross-distillation. Phys Med Biol 2024; 69:115059. [PMID: 38768601 DOI: 10.1088/1361-6560/ad4e01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2024] [Accepted: 05/20/2024] [Indexed: 05/22/2024]
Abstract
Objective.Multi-phase computed tomography (CT) has become a leading modality for identifying hepatic tumors. Nevertheless, the presence of misalignment in the images of different phases poses a challenge in accurately identifying and analyzing the patient's anatomy. Conventional registration methods typically concentrate on either intensity-based features or landmark-based features in isolation, so imposing limitations on the accuracy of the registration process.Method.We establish a nonrigid cycle-registration network that leverages semi-supervised learning techniques, wherein a point distance term based on Euclidean distance between registered landmark points is introduced into the loss function. Additionally, a cross-distillation strategy is proposed in network training to further improve registration performance which incorporates response-based knowledge concerning the distances between feature points.Results.We conducted experiments using multi-centered liver CT datasets to evaluate the performance of the proposed method. The results demonstrate that our method outperforms baseline methods in terms of target registration error. Additionally, Dice scores of the warped tumor masks were calculated. Our method consistently achieved the highest scores among all the comparing methods. Specifically, it achieved scores of 82.9% and 82.5% in the hepatocellular carcinoma and the intrahepatic cholangiocarcinoma dataset, respectively.Significance.The superior registration performance indicates its potential to serve as an important tool in hepatic tumor identification and analysis.
Collapse
Affiliation(s)
- Fan Rao
- Research Center for Augmented Intelligence, Zhejiang Lab, Hangzhou 310000, People's Republic of China
| | - Tianling Lyu
- Research Center for Augmented Intelligence, Zhejiang Lab, Hangzhou 310000, People's Republic of China
| | - Zhan Feng
- Department of Radiology, College of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou 311100, People's Republic of China
| | - Yuanfeng Wu
- Research Center for Augmented Intelligence, Zhejiang Lab, Hangzhou 310000, People's Republic of China
| | - Yangfan Ni
- Research Center for Augmented Intelligence, Zhejiang Lab, Hangzhou 310000, People's Republic of China
| | - Wentao Zhu
- Research Center for Augmented Intelligence, Zhejiang Lab, Hangzhou 310000, People's Republic of China
| |
Collapse
|
2
|
Maino C, Vernuccio F, Cannella R, Franco PN, Giannini V, Dezio M, Pisani AR, Blandino AA, Faletti R, De Bernardi E, Ippolito D, Gatti M, Inchingolo R. Radiomics and liver: Where we are and where we are headed? Eur J Radiol 2024; 171:111297. [PMID: 38237517 DOI: 10.1016/j.ejrad.2024.111297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2023] [Revised: 01/03/2024] [Accepted: 01/07/2024] [Indexed: 02/10/2024]
Abstract
Hepatic diffuse conditions and focal liver lesions represent two of the most common scenarios to face in everyday radiological clinical practice. Thanks to the advances in technology, radiology has gained a central role in the management of patients with liver disease, especially due to its high sensitivity and specificity. Since the introduction of computed tomography (CT) and magnetic resonance imaging (MRI), radiology has been considered the non-invasive reference modality to assess and characterize liver pathologies. In recent years, clinical practice has moved forward to a quantitative approach to better evaluate and manage each patient with a more fitted approach. In this setting, radiomics has gained an important role in helping radiologists and clinicians characterize hepatic pathological entities, in managing patients, and in determining prognosis. Radiomics can extract a large amount of data from radiological images, which can be associated with different liver scenarios. Thanks to its wide applications in ultrasonography (US), CT, and MRI, different studies were focused on specific aspects related to liver diseases. Even if broadly applied, radiomics has some advantages and different pitfalls. This review aims to summarize the most important and robust studies published in the field of liver radiomics, underlying their main limitations and issues, and what they can add to the current and future clinical practice and literature.
Collapse
Affiliation(s)
- Cesare Maino
- Department of Radiology, Fondazione IRCCS San Gerardo dei Tintori, Monza 20900, Italy.
| | - Federica Vernuccio
- Institute of Radiology, University Hospital of Padova, Padova 35128, Italy
| | - Roberto Cannella
- Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo 90127, Italy
| | - Paolo Niccolò Franco
- Department of Radiology, Fondazione IRCCS San Gerardo dei Tintori, Monza 20900, Italy
| | - Valentina Giannini
- Department of Surgical Sciences, University of Turin, Turin 10126, Italy
| | - Michele Dezio
- Department of Radiology, Miulli Hospital, Acquaviva delle Fonti 70021, Bari, Italy
| | - Antonio Rosario Pisani
- Nuclear Medicine Unit, Interdisciplinary Department of Medicine, University of Bari, Bari 70121, Italy
| | - Antonino Andrea Blandino
- Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo 90127, Italy
| | - Riccardo Faletti
- Department of Surgical Sciences, University of Turin, Turin 10126, Italy
| | - Elisabetta De Bernardi
- Bicocca Bioinformatics Biostatistics and Bioimaging Centre - B4, University of Milano Bicocca, Milano 20100, Italy; School of Medicine, University of Milano Bicocca, Milano 20100, Italy
| | - Davide Ippolito
- Department of Radiology, Fondazione IRCCS San Gerardo dei Tintori, Monza 20900, Italy; School of Medicine, University of Milano Bicocca, Milano 20100, Italy
| | - Marco Gatti
- Department of Surgical Sciences, University of Turin, Turin 10126, Italy
| | - Riccardo Inchingolo
- Unit of Interventional Radiology, F. Miulli Hospital, Acquaviva delle Fonti 70021, Italy
| |
Collapse
|
3
|
Huang J, Bai X, Qiu Y, He X. Application of AI on cholangiocarcinoma. Front Oncol 2024; 14:1324222. [PMID: 38347839 PMCID: PMC10859478 DOI: 10.3389/fonc.2024.1324222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Accepted: 01/08/2024] [Indexed: 02/15/2024] Open
Abstract
Cholangiocarcinoma, classified as intrahepatic, perihilar, and extrahepatic, is considered a deadly malignancy of the hepatobiliary system. Most cases of cholangiocarcinoma are asymptomatic. Therefore, early detection of cholangiocarcinoma is significant but still challenging. The routine screening of a tumor lacks specificity and accuracy. With the application of AI, high-risk patients can be easily found by analyzing their clinical characteristics, serum biomarkers, and medical images. Moreover, AI can be used to predict the prognosis including recurrence risk and metastasis. Although they have some limitations, AI algorithms will still significantly improve many aspects of cholangiocarcinoma in the medical field with the development of computing power and technology.
Collapse
Affiliation(s)
| | | | | | - Xiaodong He
- Department of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
| |
Collapse
|
4
|
Chakrabarti S, Rao US. Lightweight neural network for smart diagnosis of cholangiocarcinoma using histopathological images. Sci Rep 2023; 13:18854. [PMID: 37914815 PMCID: PMC10620203 DOI: 10.1038/s41598-023-46152-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2023] [Accepted: 10/28/2023] [Indexed: 11/03/2023] Open
Abstract
Traditional Cholangiocarcinoma detection methodology, which involves manual interpretation of histopathological images obtained after biopsy, necessitates extraordinary domain expertise and a significant level of subjectivity, resulting in several deaths due to improper or delayed detection of this cancer that develops in the bile duct lining. Automation in the diagnosis of this dreadful disease is desperately needed to allow for more effective and faster identification of the disease with a better degree of accuracy and reliability, ultimately saving countless human lives. The primary goal of this study is to develop a machine-assisted method of automation for the accurate and rapid identification of Cholangiocarcinoma utilizing histopathology images with little preprocessing. This work proposes CholangioNet, a novel lightweight neural network for detecting Cholangiocarcinoma utilizing histological RGB images. The histological RGB image dataset considered in this research work was found to have limited number of images, hence data augmentation was performed to increase the number of images. The finally obtained dataset was then subjected to minimal preprocessing procedures. These preprocessed images were then fed into the proposed lightweight CholangioNet. The performance of this proposed architecture is then compared with the performance of some of the prominent existing architectures like, VGG16, VGG19, ResNet50 and ResNet101. The Accuracy, Loss, Precision, and Sensitivity metrics are used to assess the efficiency of the proposed system. At 200 epochs, the proposed architecture achieves maximum training accuracy, precision, and recall of 99.90%, 100%, and 100%, respectively. The suggested architecture's validation accuracy, precision, and recall are 98.40%, 100%, and 100%, respectively. When compared to the performance of other AI-based models, the proposed system produced better results making it a potential AI tool for real world application.
Collapse
Affiliation(s)
- Shubhadip Chakrabarti
- School of Computer Science and Engineering, Vellore Institute of Technology, Chennai Campus, Chennai, Tamil Nadu, 600127, India
| | - Ummity Srinivasa Rao
- School of Computer Science and Engineering, Vellore Institute of Technology, Chennai Campus, Chennai, Tamil Nadu, 600127, India.
| |
Collapse
|
5
|
Radiya K, Joakimsen HL, Mikalsen KØ, Aahlin EK, Lindsetmo RO, Mortensen KE. Performance and clinical applicability of machine learning in liver computed tomography imaging: a systematic review. Eur Radiol 2023; 33:6689-6717. [PMID: 37171491 PMCID: PMC10511359 DOI: 10.1007/s00330-023-09609-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2022] [Revised: 02/02/2023] [Accepted: 02/06/2023] [Indexed: 05/13/2023]
Abstract
OBJECTIVES Machine learning (ML) for medical imaging is emerging for several organs and image modalities. Our objectives were to provide clinicians with an overview of this field by answering the following questions: (1) How is ML applied in liver computed tomography (CT) imaging? (2) How well do ML systems perform in liver CT imaging? (3) What are the clinical applications of ML in liver CT imaging? METHODS A systematic review was carried out according to the guidelines from the PRISMA-P statement. The search string focused on studies containing content relating to artificial intelligence, liver, and computed tomography. RESULTS One hundred ninety-one studies were included in the study. ML was applied to CT liver imaging by image analysis without clinicians' intervention in majority of studies while in newer studies the fusion of ML method with clinical intervention have been identified. Several were documented to perform very accurately on reliable but small data. Most models identified were deep learning-based, mainly using convolutional neural networks. Potentially many clinical applications of ML to CT liver imaging have been identified through our review including liver and its lesion segmentation and classification, segmentation of vascular structure inside the liver, fibrosis and cirrhosis staging, metastasis prediction, and evaluation of chemotherapy. CONCLUSION Several studies attempted to provide transparent result of the model. To make the model convenient for a clinical application, prospective clinical validation studies are in urgent call. Computer scientists and engineers should seek to cooperate with health professionals to ensure this. KEY POINTS • ML shows great potential for CT liver image tasks such as pixel-wise segmentation and classification of liver and liver lesions, fibrosis staging, metastasis prediction, and retrieval of relevant liver lesions from similar cases of other patients. • Despite presenting the result is not standardized, many studies have attempted to provide transparent results to interpret the machine learning method performance in the literature. • Prospective studies are in urgent call for clinical validation of ML method, preferably carried out by cooperation between clinicians and computer scientists.
Collapse
Affiliation(s)
- Keyur Radiya
- Department of Gastroenterological Surgery at University Hospital of North Norway (UNN), Tromso, Norway.
- Department of Clinical Medicine, UiT The Arctic University of Norway, Tromso, Norway.
| | - Henrik Lykke Joakimsen
- Institute of Clinical Medicine, UiT The Arctic University of Norway, Tromso, Norway
- Centre for Clinical Artificial Intelligence (SPKI), University Hospital of North Norway, Tromso, Norway
| | - Karl Øyvind Mikalsen
- Department of Clinical Medicine, UiT The Arctic University of Norway, Tromso, Norway
- Centre for Clinical Artificial Intelligence (SPKI), University Hospital of North Norway, Tromso, Norway
- UiT Machine Learning Group, Department of Physics and Technology, UiT the Arctic University of Norway, Tromso, Norway
| | - Eirik Kjus Aahlin
- Department of Gastroenterological Surgery at University Hospital of North Norway (UNN), Tromso, Norway
| | - Rolv-Ole Lindsetmo
- Department of Clinical Medicine, UiT The Arctic University of Norway, Tromso, Norway
- Head Clinic of Surgery, Oncology and Women Health, University Hospital of North Norway, Tromso, Norway
| | - Kim Erlend Mortensen
- Department of Gastroenterological Surgery at University Hospital of North Norway (UNN), Tromso, Norway
- Department of Clinical Medicine, UiT The Arctic University of Norway, Tromso, Norway
| |
Collapse
|
6
|
Mervak BM, Fried JG, Wasnik AP. A Review of the Clinical Applications of Artificial Intelligence in Abdominal Imaging. Diagnostics (Basel) 2023; 13:2889. [PMID: 37761253 PMCID: PMC10529018 DOI: 10.3390/diagnostics13182889] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2023] [Revised: 08/23/2023] [Accepted: 09/05/2023] [Indexed: 09/29/2023] Open
Abstract
Artificial intelligence (AI) has been a topic of substantial interest for radiologists in recent years. Although many of the first clinical applications were in the neuro, cardiothoracic, and breast imaging subspecialties, the number of investigated and real-world applications of body imaging has been increasing, with more than 30 FDA-approved algorithms now available for applications in the abdomen and pelvis. In this manuscript, we explore some of the fundamentals of artificial intelligence and machine learning, review major functions that AI algorithms may perform, introduce current and potential future applications of AI in abdominal imaging, provide a basic understanding of the pathways by which AI algorithms can receive FDA approval, and explore some of the challenges with the implementation of AI in clinical practice.
Collapse
Affiliation(s)
| | | | - Ashish P. Wasnik
- Department of Radiology, University of Michigan—Michigan Medicine, 1500 E. Medical Center Dr., Ann Arbor, MI 48109, USA; (B.M.M.); (J.G.F.)
| |
Collapse
|
7
|
Shahbazian H, Mirza-Aghazadeh-Attari M, Borhani A, Mohseni A, Madani SP, Ansari G, Pawlik TM, Kamel IR. Multimodality imaging of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Surg Oncol 2023; 128:519-530. [PMID: 37439096 DOI: 10.1002/jso.27396] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2023] [Revised: 07/03/2023] [Accepted: 07/04/2023] [Indexed: 07/14/2023]
Abstract
Hepatocellular carcinoma and intrahepatic cholangiocarcinoma are the two most common primary malignant tumors of the liver. The similarities and variations in imaging characteristics that may aid in distinguishing between these two primary tumors will be discussed and outlined in this review. Knowledge of imaging techniques that are currently available would assist in the differentiation between these primary malignancies.
Collapse
Affiliation(s)
- Haneyeh Shahbazian
- Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Mohammad Mirza-Aghazadeh-Attari
- Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Ali Borhani
- Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Alireza Mohseni
- Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Seyedeh Panid Madani
- Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Golnoosh Ansari
- Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Timothy M Pawlik
- Department of Surgery, The Ohio State University Wexner Medical Center, and James Cancer Center, Columbus, Ohio, USA
| | - Ihab R Kamel
- Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| |
Collapse
|
8
|
Chen X, Chen Y, Chen H, Zhu J, Huang R, Xie J, Zhang T, Xie A, Li Y. Machine learning based on gadoxetic acid-enhanced MRI for differentiating atypical intrahepatic mass-forming cholangiocarcinoma from poorly differentiated hepatocellular carcinoma. Abdom Radiol (NY) 2023; 48:2525-2536. [PMID: 37169988 DOI: 10.1007/s00261-023-03870-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2022] [Revised: 02/23/2023] [Accepted: 02/23/2023] [Indexed: 05/13/2023]
Abstract
PURPOSE The study was to develop a Gd-EOB-DTPA-enhanced MRI radiomics model for differentiating atypical intrahepatic mass-forming cholangiocarcinoma (aIMCC) from poorly differentiated hepatocellular carcinoma (pHCC). MATERIALS AND METHODS A total of 134 patients (51 aIMCC and 83 pHCC) who underwent Gadoxetic acid-enhanced MRI between March 2016 and March 2022 were enrolled in this study and then randomly assigned to the training and validation cohorts by 7:3 (93 patients and 41 patients, respectively). The radiomics features were extracted from the hepatobiliary phase of Gadoxetic acid-enhanced MRI. In the training cohort, the SelectKBest and the least absolute shrinkage and selection operator (LASSO) were used to select the radiomics features. The clinical, radiomics, and clinical-radiomics model were established using four machine learning algorithms. The performance of the model was evaluated by the receiver operating characteristic (ROC) curve. Comparison of the radiomics and clinical-radiomics model was done by the Delong test. The clinical usefulness of the model was evaluated using decision curve analysis (DCA). RESULTS In 1132 extracted radiomic features, 15 were selected to develop radiomics signature. For identifying aIMCC and pHCC, the radiomics model constructed by random forest algorithm showed the high performance (AUC = 0.90) in the training cohort. The performance of the clinical-radiomics model (AUC = 0.89) was not significantly different (P = 0.88) from that of the radiomics model constructed by random forest algorithm (AUC = 0.86) in the validation cohort. DCA demonstrated that the clinical-radiomics model constructed by random forest algorithm had a high net clinical benefit. CONCLUSION The clinical-radiomics model is an effective tool to distinguish aIMCC from pHCC and may provide additional value for the development of treatment plans.
Collapse
Affiliation(s)
- Xiang Chen
- Department of Radiology, the First Affiliated Hospital of Soochow University, Suzhou, 215000, Jiangsu, People's Republic of China
| | - Ying Chen
- Department of Radiology, Affiliated Nantong Hospital 3 of Nantong University, Youth Middle Road 60#, Nantong, Jiangsu, People's Republic of China
| | - Haobo Chen
- Department of Radiology, Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University), NO.61 Jiefang East Road, Changsha, 410005, Hunan, People's Republic of China
| | - Jingfen Zhu
- Department of Radiology, the First Affiliated Hospital of Soochow University, Suzhou, 215000, Jiangsu, People's Republic of China
| | - Renjun Huang
- Department of Radiology, the First Affiliated Hospital of Soochow University, Suzhou, 215000, Jiangsu, People's Republic of China
| | - Junjian Xie
- Department of Radiology, the First Affiliated Hospital of Soochow University, Suzhou, 215000, Jiangsu, People's Republic of China
- Department of Radiology, Affiliated Hospital of Jiangnan, Wuxi, 214086, People's Republic of China
| | - Tao Zhang
- Department of Radiology, Affiliated Nantong Hospital 3 of Nantong University, Youth Middle Road 60#, Nantong, Jiangsu, People's Republic of China.
| | - An Xie
- Department of Radiology, the First Affiliated Hospital of Soochow University, Suzhou, 215000, Jiangsu, People's Republic of China.
- Department of Radiology, Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University), NO.61 Jiefang East Road, Changsha, 410005, Hunan, People's Republic of China.
| | - Yonggang Li
- Department of Radiology, the First Affiliated Hospital of Soochow University, Suzhou, 215000, Jiangsu, People's Republic of China.
- Institute of Medical Imaging, Soochow University, Suzhou, Jiangsu, 215000, People's Republic of China.
- National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Shizi Street 188#, Suzhou, Jiangsu, 215000, People's Republic of China.
- Suzhou Key Laboratory of Intelligent Medicine and Equipment, Suzhou, 215123, People's Republic of China.
| |
Collapse
|
9
|
Zhang X, Jia N, Wang Y. Multi-input dense convolutional network for classification of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Biomed Signal Process Control 2023. [DOI: 10.1016/j.bspc.2022.104226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
10
|
Cannella R, Vernuccio F, Klontzas ME, Ponsiglione A, Petrash E, Ugga L, Pinto dos Santos D, Cuocolo R. Systematic review with radiomics quality score of cholangiocarcinoma: an EuSoMII Radiomics Auditing Group Initiative. Insights Imaging 2023; 14:21. [PMID: 36720726 PMCID: PMC9889586 DOI: 10.1186/s13244-023-01365-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2022] [Accepted: 12/24/2022] [Indexed: 02/02/2023] Open
Abstract
OBJECTIVES To systematically review current research applications of radiomics in patients with cholangiocarcinoma and to assess the quality of CT and MRI radiomics studies. METHODS A systematic search was conducted on PubMed/Medline, Web of Science, and Scopus databases to identify original studies assessing radiomics of cholangiocarcinoma on CT and/or MRI. Three readers with different experience levels independently assessed quality of the studies using the radiomics quality score (RQS). Subgroup analyses were performed according to journal type, year of publication, quartile and impact factor (from the Journal Citation Report database), type of cholangiocarcinoma, imaging modality, and number of patients. RESULTS A total of 38 original studies including 6242 patients (median 134 patients) were selected. The median RQS was 9 (corresponding to 25.0% of the total RQS; IQR 1-13) for reader 1, 8 (22.2%, IQR 3-12) for reader 2, and 10 (27.8%; IQR 5-14) for reader 3. The inter-reader agreement was good with an ICC of 0.75 (95% CI 0.62-0.85) for the total RQS. All studies were retrospective and none of them had phantom assessment, imaging at multiple time points, nor performed cost-effectiveness analysis. The RQS was significantly higher in studies published in journals with impact factor > 4 (median 11 vs. 4, p = 0.048 for reader 1) and including more than 100 patients (median 11.5 vs. 0.5, p < 0.001 for reader 1). CONCLUSIONS Quality of radiomics studies on cholangiocarcinoma is insufficient based on the radiomics quality score. Future research should consider prospective studies with a standardized methodology, validation in multi-institutional external cohorts, and open science data.
Collapse
Affiliation(s)
- Roberto Cannella
- Section of Radiology - Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University Hospital “Paolo Giaccone”, Via del Vespro 129, 90127 Palermo, Italy ,grid.10776.370000 0004 1762 5517Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Via del Vespro, 129, 90127 Palermo, Italy
| | - Federica Vernuccio
- grid.411474.30000 0004 1760 2630Department of Radiology, University Hospital of Padova, Via Nicolò Giustiniani 2, 35128 Padua, Italy
| | - Michail E. Klontzas
- grid.412481.a0000 0004 0576 5678Department of Medical Imaging, University Hospital of Heraklion, 71110 Voutes, Crete, Greece ,grid.8127.c0000 0004 0576 3437Department of Radiology, School of Medicine, University of Crete, 71003 Heraklion, Crete, Greece ,grid.4834.b0000 0004 0635 685XComputational Biomedicine Laboratory, Institute of Computer Science, Foundation for Research and Technology, Vassilika Vouton, 70013 Crete, Greece
| | - Andrea Ponsiglione
- grid.4691.a0000 0001 0790 385XDepartment of Advanced Biomedical Sciences, University of Naples “Federico II”, Via Sergio Pansini 5, 80131 Naples, Italy
| | - Ekaterina Petrash
- grid.415738.c0000 0000 9216 2496Radiology Department Research Institute of Children’s Oncology and Hematology, FSBI “National Medical Research Center of Oncology n.a. N.N. Blokhin” of Ministry of Health of RF, Kashirskoye Highway 24, Moscow, Russia ,IRA-Labs, Medical Department, Skolkovo, Bolshoi Boulevard, 30, Building 1, Moscow, Russia
| | - Lorenzo Ugga
- grid.4691.a0000 0001 0790 385XDepartment of Advanced Biomedical Sciences, University of Naples “Federico II”, Via Sergio Pansini 5, 80131 Naples, Italy
| | - Daniel Pinto dos Santos
- grid.6190.e0000 0000 8580 3777Department of Diagnostic and Interventional Radiology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany ,grid.411088.40000 0004 0578 8220Department of Radiology, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
| | - Renato Cuocolo
- grid.11780.3f0000 0004 1937 0335Department of Medicine, Surgery, and Dentistry, University of Salerno, Via Salvador Allende 43, 84081 Baronissi, SA Italy ,grid.4691.a0000 0001 0790 385XAugmented Reality for Health Monitoring Laboratory (ARHeMLab), Department of Electrical Engineering and Information Technology, University of Naples “Federico II”, Via Sergio Pansini 5, 80131 Naples, Italy
| |
Collapse
|
11
|
Artificial intelligence: A review of current applications in hepatocellular carcinoma imaging. Diagn Interv Imaging 2023; 104:24-36. [PMID: 36272931 DOI: 10.1016/j.diii.2022.10.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2022] [Accepted: 10/03/2022] [Indexed: 01/10/2023]
Abstract
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and currently the third-leading cause of cancer-related death worldwide. Recently, artificial intelligence (AI) has emerged as an important tool to improve clinical management of HCC, including for diagnosis, prognostication and evaluation of treatment response. Different AI approaches, such as machine learning and deep learning, are both based on the concept of developing prediction algorithms from large amounts of data, or big data. The era of digital medicine has led to a rapidly expanding amount of routinely collected health data which can be leveraged for the development of AI models. Various studies have constructed AI models by using features extracted from ultrasound imaging, computed tomography imaging and magnetic resonance imaging. Most of these models have used convolutional neural networks. These tools have shown promising results for HCC detection, characterization of liver lesions and liver/tumor segmentation. Regarding treatment, studies have outlined a role for AI in evaluation of treatment response and improvement of pre-treatment planning. Several challenges remain to fully integrate AI models in clinical practice. Future research is still needed to robustly evaluate AI algorithms in prospective trials, and improve interpretability, generalizability and transparency. If such challenges can be overcome, AI has the potential to profoundly change the management of patients with HCC. The purpose of this review was to sum up current evidence on AI approaches using imaging for the clinical management of HCC.
Collapse
|
12
|
Liu Y, Wang B, Mo X, Tang K, He J, Hao J. A Deep Learning Workflow for Mass-Forming Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma Classification Based on MRI. Curr Oncol 2022; 30:529-544. [PMID: 36661691 PMCID: PMC9857958 DOI: 10.3390/curroncol30010042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2022] [Revised: 12/21/2022] [Accepted: 12/27/2022] [Indexed: 01/04/2023] Open
Abstract
OBJECTIVE Precise classification of mass-forming intrahepatic cholangiocarcinoma (MF-ICC) and hepatocellular carcinoma (HCC) based on magnetic resonance imaging (MRI) is crucial for personalized treatment strategy. The purpose of the present study was to differentiate MF-ICC from HCC applying a novel deep-learning-based workflow with stronger feature extraction ability and fusion capability to improve the classification performance of deep learning on small datasets. METHODS To retain more effective lesion features, we propose a preprocessing method called semi-segmented preprocessing (Semi-SP) to select the region of interest (ROI). Then, the ROIs were sent to the strided feature fusion residual network (SFFNet) for training and classification. The SFFNet model is composed of three parts: the multilayer feature fusion module (MFF) was proposed to extract discriminative features of MF-ICC/HCC and integrate features of different levels; a new stationary residual block (SRB) was proposed to solve the problem of information loss and network instability during training; the attention mechanism convolutional block attention module (CBAM) was adopted in the middle layer of the network to extract the correlation of multi-spatial feature information, so as to filter the irrelevant feature information in pixels. RESULTS The SFFNet model achieved an overall accuracy of 92.26% and an AUC of 0.9680, with high sensitivity (86.21%) and specificity (94.70%) for MF-ICC. CONCLUSION In this paper, we proposed a specifically designed Semi-SP method and SFFNet model to differentiate MF-ICC from HCC. This workflow achieves good MF-ICC/HCC classification performance due to stronger feature extraction and fusion capabilities, which provide complementary information for personalized treatment strategy.
Collapse
Affiliation(s)
- Yangling Liu
- Faculty of Information Engineering and Automation, Kunming University of Science and Technology, Kunming 650504, China
| | - Bin Wang
- Department of Radiology, Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China
| | - Xiao Mo
- Faculty of Information Engineering and Automation, Kunming University of Science and Technology, Kunming 650504, China
| | - Kang Tang
- Department of Radiology, Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China
| | - Jianfeng He
- Faculty of Information Engineering and Automation, Kunming University of Science and Technology, Kunming 650504, China
| | - Jingang Hao
- Department of Radiology, Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China
| |
Collapse
|
13
|
Fahmy D, Alksas A, Elnakib A, Mahmoud A, Kandil H, Khalil A, Ghazal M, van Bogaert E, Contractor S, El-Baz A. The Role of Radiomics and AI Technologies in the Segmentation, Detection, and Management of Hepatocellular Carcinoma. Cancers (Basel) 2022; 14:cancers14246123. [PMID: 36551606 PMCID: PMC9777232 DOI: 10.3390/cancers14246123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2022] [Revised: 12/08/2022] [Accepted: 12/09/2022] [Indexed: 12/15/2022] Open
Abstract
Hepatocellular carcinoma (HCC) is the most common primary hepatic neoplasm. Thanks to recent advances in computed tomography (CT) and magnetic resonance imaging (MRI), there is potential to improve detection, segmentation, discrimination from HCC mimics, and monitoring of therapeutic response. Radiomics, artificial intelligence (AI), and derived tools have already been applied in other areas of diagnostic imaging with promising results. In this review, we briefly discuss the current clinical applications of radiomics and AI in the detection, segmentation, and management of HCC. Moreover, we investigate their potential to reach a more accurate diagnosis of HCC and to guide proper treatment planning.
Collapse
Affiliation(s)
- Dalia Fahmy
- Diagnostic Radiology Department, Mansoura University Hospital, Mansoura 35516, Egypt
| | - Ahmed Alksas
- Bioengineering Department, University of Louisville, Louisville, KY 40292, USA
| | - Ahmed Elnakib
- Bioengineering Department, University of Louisville, Louisville, KY 40292, USA
| | - Ali Mahmoud
- Bioengineering Department, University of Louisville, Louisville, KY 40292, USA
| | - Heba Kandil
- Bioengineering Department, University of Louisville, Louisville, KY 40292, USA
- Faculty of Computer Sciences and Information, Mansoura University, Mansoura 35516, Egypt
| | - Ashraf Khalil
- College of Technological Innovation, Zayed University, Abu Dhabi 4783, United Arab Emirates
| | - Mohammed Ghazal
- Electrical, Computer, and Biomedical Engineering Department, Abu Dhabi University, Abu Dhabi 59911, United Arab Emirates
| | - Eric van Bogaert
- Department of Radiology, University of Louisville, Louisville, KY 40202, USA
| | - Sohail Contractor
- Department of Radiology, University of Louisville, Louisville, KY 40202, USA
| | - Ayman El-Baz
- Bioengineering Department, University of Louisville, Louisville, KY 40292, USA
- Correspondence:
| |
Collapse
|
14
|
Ding L, Ning S, Hu W, Xue Y, Yu S. Distinctive Metabolism-Associated Gene Clusters That Are Also Prognostic in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 2022; 2022:6595989. [PMID: 36199423 PMCID: PMC9527115 DOI: 10.1155/2022/6595989] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/02/2022] [Revised: 08/22/2022] [Accepted: 08/29/2022] [Indexed: 11/29/2022]
Abstract
Objective To offer new prognostic evaluations by exploring potentially distinctive genetic features of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). Methods There were 12 samples for gene expression profiling processes in this study. These included three HCC lesion samples and their matched adjacent nontumor liver tissues obtained from patients with HCC, as well as three ICC samples and their controls collected similarly. In addition to the expression matrix generated on our own, profiles of other cohorts from The Cancer Genome Atlas (TCGA) program and the Gene Expression Omnibus (GEO) were also employed in later bioinformatical analyses. Differential analyses, functional analyses, protein interaction network analyses, and gene set variation analyses were used to identify key genes. To establish the prognostic models, univariate/multivariate Cox analyses and subsequent stepwise regression were applied, with the Akaike information criterion evaluating the goodness of fitness. Results The top three pathways enriched in HCC were all metabolism-related; they were fatty acid degradation, retinol metabolism, and arachidonic acid metabolism. In ICC, on the other hand, additional pathways related to fat digestion and absorption and cholesterol metabolism were identified. Consistent characteristics of such a metabolic landscape were observed across different cohorts. A prognostic risk score model for calculating HCC risk was constructed, consisting of ADH4, ADH6, CYP2C9, CYP4F2, and RDH16. This signature predicts the 3-year survival with an AUC area of 0.708 (95%CI = 0.644 to 0.772). For calculating the risk of ICC, a prognostic risk score model was built upon the expression levels of CYP26A1, NAT2, and UGT2B10. This signature predicts the 3-year survival with an AUC area of 0.806 (95% CI = 0.664 to 0.947). Conclusion HCC and ICC share commonly abrupted pathways associated with the metabolism of fatty acids, retinol, arachidonic acids, and drugs, indicating similarities in their pathogenesis as primary liver cancers. On the flip side, these two types of cancer possess distinctive promising biomarkers for predicting overall survival or potential targeted therapies.
Collapse
Affiliation(s)
- Linchao Ding
- Central Laboratory, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China
| | - Shilong Ning
- Department of Clinical Nutrition, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China
| | - Weijian Hu
- Department of Hepatobiliary and Pancreatic Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China
| | - Yadong Xue
- Central Laboratory, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China
| | - Shi'an Yu
- Department of Hepatobiliary and Pancreatic Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China
| |
Collapse
|
15
|
De Muzio F, Grassi F, Dell’Aversana F, Fusco R, Danti G, Flammia F, Chiti G, Valeri T, Agostini A, Palumbo P, Bruno F, Cutolo C, Grassi R, Simonetti I, Giovagnoni A, Miele V, Barile A, Granata V. A Narrative Review on LI-RADS Algorithm in Liver Tumors: Prospects and Pitfalls. Diagnostics (Basel) 2022; 12:diagnostics12071655. [PMID: 35885561 PMCID: PMC9319674 DOI: 10.3390/diagnostics12071655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2022] [Revised: 06/27/2022] [Accepted: 07/05/2022] [Indexed: 11/16/2022] Open
Abstract
Liver cancer is the sixth most detected tumor and the third leading cause of tumor death worldwide. Hepatocellular carcinoma (HCC) is the most common primary liver malignancy with specific risk factors and a targeted population. Imaging plays a major role in the management of HCC from screening to post-therapy follow-up. In order to optimize the diagnostic-therapeutic management and using a universal report, which allows more effective communication among the multidisciplinary team, several classification systems have been proposed over time, and LI-RADS is the most utilized. Currently, LI-RADS comprises four algorithms addressing screening and surveillance, diagnosis on computed tomography (CT)/magnetic resonance imaging (MRI), diagnosis on contrast-enhanced ultrasound (CEUS) and treatment response on CT/MRI. The algorithm allows guiding the radiologist through a stepwise process of assigning a category to a liver observation, recognizing both major and ancillary features. This process allows for characterizing liver lesions and assessing treatment. In this review, we highlighted both major and ancillary features that could define HCC. The distinctive dynamic vascular pattern of arterial hyperenhancement followed by washout in the portal-venous phase is the key hallmark of HCC, with a specificity value close to 100%. However, the sensitivity value of these combined criteria is inadequate. Recent evidence has proven that liver-specific contrast could be an important tool not only in increasing sensitivity but also in diagnosis as a major criterion. Although LI-RADS emerges as an essential instrument to support the management of liver tumors, still many improvements are needed to overcome the current limitations. In particular, features that may clearly distinguish HCC from cholangiocarcinoma (CCA) and combined HCC-CCA lesions and the assessment after locoregional radiation-based therapy are still fields of research.
Collapse
Affiliation(s)
- Federica De Muzio
- Department of Medicine and Health Sciences V. Tiberio, University of Molise, 86100 Campobasso, Italy;
| | - Francesca Grassi
- Division of Radiology, Università degli Studi della Campania Luigi Vanvitelli, 81100 Naples, Italy; (F.G.); (F.D.); (R.G.)
| | - Federica Dell’Aversana
- Division of Radiology, Università degli Studi della Campania Luigi Vanvitelli, 81100 Naples, Italy; (F.G.); (F.D.); (R.G.)
| | - Roberta Fusco
- Medical Oncology Division, Igea SpA, 80013 Naples, Italy
- Correspondence:
| | - Ginevra Danti
- Division of Radiology, Azienda Ospedaliera Universitaria Careggi, 50134 Florence, Italy; (G.D.); (F.F.); (G.C.); (V.M.)
- Italian Society of Medical and Interventional Radiology (SIRM), SIRM Foundation, 20122 Milan, Italy; (P.P.); (F.B.)
| | - Federica Flammia
- Division of Radiology, Azienda Ospedaliera Universitaria Careggi, 50134 Florence, Italy; (G.D.); (F.F.); (G.C.); (V.M.)
- Italian Society of Medical and Interventional Radiology (SIRM), SIRM Foundation, 20122 Milan, Italy; (P.P.); (F.B.)
| | - Giuditta Chiti
- Division of Radiology, Azienda Ospedaliera Universitaria Careggi, 50134 Florence, Italy; (G.D.); (F.F.); (G.C.); (V.M.)
- Italian Society of Medical and Interventional Radiology (SIRM), SIRM Foundation, 20122 Milan, Italy; (P.P.); (F.B.)
| | - Tommaso Valeri
- Department of Clinical Special and Dental Sciences, University Politecnica delle Marche, 60126 Ancona, Italy; (T.V.); (A.A.); (A.G.)
- Department of Radiological Sciences, University Hospital Ospedali Riuniti, Via Tronto 10/a, 60126 Torrette, Italy
| | - Andrea Agostini
- Department of Clinical Special and Dental Sciences, University Politecnica delle Marche, 60126 Ancona, Italy; (T.V.); (A.A.); (A.G.)
- Department of Radiological Sciences, University Hospital Ospedali Riuniti, Via Tronto 10/a, 60126 Torrette, Italy
| | - Pierpaolo Palumbo
- Italian Society of Medical and Interventional Radiology (SIRM), SIRM Foundation, 20122 Milan, Italy; (P.P.); (F.B.)
- Area of Cardiovascular and Interventional Imaging, Department of Diagnostic Imaging, Abruzzo Health Unit 1, 67100 L’Aquila, Italy
| | - Federico Bruno
- Italian Society of Medical and Interventional Radiology (SIRM), SIRM Foundation, 20122 Milan, Italy; (P.P.); (F.B.)
- Emergency Radiology, San Salvatore Hospital, Via Lorenzo Natali 1, 67100 L’Aquila, Italy;
| | - Carmen Cutolo
- Department of Medicine, Surgery and Dentistry, University of Salerno, 84084 Fisciano, Italy;
| | - Roberta Grassi
- Division of Radiology, Università degli Studi della Campania Luigi Vanvitelli, 81100 Naples, Italy; (F.G.); (F.D.); (R.G.)
- Italian Society of Medical and Interventional Radiology (SIRM), SIRM Foundation, 20122 Milan, Italy; (P.P.); (F.B.)
| | - Igino Simonetti
- Radiology Division, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Via Mariano Semmola, 80131 Naples, Italy; (I.S.); (V.G.)
| | - Andrea Giovagnoni
- Department of Clinical Special and Dental Sciences, University Politecnica delle Marche, 60126 Ancona, Italy; (T.V.); (A.A.); (A.G.)
- Department of Radiological Sciences, University Hospital Ospedali Riuniti, Via Tronto 10/a, 60126 Torrette, Italy
| | - Vittorio Miele
- Division of Radiology, Azienda Ospedaliera Universitaria Careggi, 50134 Florence, Italy; (G.D.); (F.F.); (G.C.); (V.M.)
- Italian Society of Medical and Interventional Radiology (SIRM), SIRM Foundation, 20122 Milan, Italy; (P.P.); (F.B.)
| | - Antonio Barile
- Emergency Radiology, San Salvatore Hospital, Via Lorenzo Natali 1, 67100 L’Aquila, Italy;
| | - Vincenza Granata
- Radiology Division, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Via Mariano Semmola, 80131 Naples, Italy; (I.S.); (V.G.)
| |
Collapse
|
16
|
Combined Hepatocellular-Cholangiocarcinoma: What the Multidisciplinary Team Should Know. Diagnostics (Basel) 2022; 12:diagnostics12040890. [PMID: 35453938 PMCID: PMC9026907 DOI: 10.3390/diagnostics12040890] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2022] [Revised: 04/01/2022] [Accepted: 04/01/2022] [Indexed: 12/10/2022] Open
Abstract
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare type of primary liver malignancy. Among the risk factors, hepatitis B and hepatitis C virus infections, cirrhosis, and male gender are widely reported. The clinical appearance of cHCC-CCA is similar to that of HCC and iCCA and it is usually silent until advanced states, causing a delay of diagnosis. Diagnosis is mainly based on histology from biopsies or surgical specimens. Correct pre-surgical diagnosis during imaging studies is very problematic and is due to the heterogeneous characteristics of the lesion in imaging, with overlapping features of HCC and CCA. The predominant histological subtype within the lesion establishes the predominant imaging findings. Therefore, in this scenario, the radiological findings characteristic of HCC show an overlap with those of CCA. Since cHCC-CCAs are prevalent in patients at high risk of HCC and there is a risk that these may mimic HCC, it is currently difficult to see a non-invasive diagnosis of HCC. Surgery is the only curative treatment of HCC-CCA. The role of liver transplantation (LT) in the treatment of cHCC-CCA remains controversial, as is the role of ablative or systemic therapies in the treatment of this tumour. These lesions still remain challenging, both in diagnosis and in the treatment phase. Therefore, a pre-treatment imaging diagnosis is essential, as well as the identification of prognostic factors that could stratify the risk of recurrence and the most adequate therapy according to patient characteristics.
Collapse
|
17
|
Artificial intelligence in gastrointestinal and hepatic imaging: past, present and future scopes. Clin Imaging 2022; 87:43-53. [DOI: 10.1016/j.clinimag.2022.04.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2021] [Revised: 03/09/2022] [Accepted: 04/11/2022] [Indexed: 11/19/2022]
|
18
|
Granata V, Fusco R, Belli A, Borzillo V, Palumbo P, Bruno F, Grassi R, Ottaiano A, Nasti G, Pilone V, Petrillo A, Izzo F. Conventional, functional and radiomics assessment for intrahepatic cholangiocarcinoma. Infect Agent Cancer 2022; 17:13. [PMID: 35346300 PMCID: PMC8961950 DOI: 10.1186/s13027-022-00429-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2022] [Accepted: 03/18/2022] [Indexed: 02/08/2023] Open
Abstract
Background This paper offers an assessment of diagnostic tools in the evaluation of Intrahepatic Cholangiocarcinoma (ICC). Methods Several electronic datasets were analysed to search papers on morphological and functional evaluation in ICC patients. Papers published in English language has been scheduled from January 2010 to December 2021.
Results We found that 88 clinical studies satisfied our research criteria. Several functional parameters and morphological elements allow a truthful ICC diagnosis. The contrast medium evaluation, during the different phases of contrast studies, support the recognition of several distinctive features of ICC. The imaging tool to employed and the type of contrast medium in magnetic resonance imaging, extracellular or hepatobiliary, should change considering patient, departement, and regional features. Also, Radiomics is an emerging area in the evaluation of ICCs. Post treatment studies are required to evaluate the efficacy and the safety of therapies so as the patient surveillance. Conclusions Several morphological and functional data obtained during Imaging studies allow a truthful ICC diagnosis.
Collapse
|
19
|
Haghbin H, Aziz M. Artificial intelligence and cholangiocarcinoma: Updates and prospects. World J Clin Oncol 2022; 13:125-134. [PMID: 35316928 PMCID: PMC8894273 DOI: 10.5306/wjco.v13.i2.125] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/09/2021] [Revised: 01/09/2022] [Accepted: 01/25/2022] [Indexed: 02/06/2023] Open
Abstract
Artificial intelligence (AI) is the timeliest field of computer science and attempts to mimic cognitive function of humans to solve problems. In the era of “Big data”, there is an ever-increasing need for AI in all aspects of medicine. Cholangiocarcinoma (CCA) is the second most common primary malignancy of liver that has shown an increase in incidence in the last years. CCA has high mortality as it is diagnosed in later stages that decreases effect of surgery, chemotherapy, and other modalities. With technological advancement there is an immense amount of clinicopathologic, genetic, serologic, histologic, and radiologic data that can be assimilated together by modern AI tools for diagnosis, treatment, and prognosis of CCA. The literature shows that in almost all cases AI models have the capacity to increase accuracy in diagnosis, treatment, and prognosis of CCA. Most studies however are retrospective, and one study failed to show AI benefit in practice. There is immense potential for AI in diagnosis, treatment, and prognosis of CCA however limitations such as relative lack of studies in use by human operators in improvement of survival remains to be seen.
Collapse
Affiliation(s)
- Hossein Haghbin
- Department of Gastroenterology, Ascension Providence Southfield, Southfield, MI 48075, United States
| | - Muhammad Aziz
- Department of Gastroenterology, University of Toledo Medical Center, Toledo, OH 43614, United States
| |
Collapse
|
20
|
Gao R, Zhao S, Aishanjiang K, Cai H, Wei T, Zhang Y, Liu Z, Zhou J, Han B, Wang J, Ding H, Liu Y, Xu X, Yu Z, Gu J. Deep learning for differential diagnosis of malignant hepatic tumors based on multi-phase contrast-enhanced CT and clinical data. J Hematol Oncol 2021; 14:154. [PMID: 34565412 PMCID: PMC8474892 DOI: 10.1186/s13045-021-01167-2] [Citation(s) in RCA: 37] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Accepted: 09/09/2021] [Indexed: 11/17/2022] Open
Abstract
Background Liver cancer remains the leading cause of cancer death globally, and the treatment strategies are distinct for each type of malignant hepatic tumors. However, the differential diagnosis before surgery is challenging and subjective. This study aims to build an automatic diagnostic model for differentiating malignant hepatic tumors based on patients’ multimodal medical data including multi-phase contrast-enhanced computed tomography and clinical features. Methods Our study consisted of 723 patients from two centers, who were pathologically diagnosed with HCC, ICC or metastatic liver cancer. The training set and the test set consisted of 499 and 113 patients from center 1, respectively. The external test set consisted of 111 patients from center 2. We proposed a deep learning model with the modular design of SpatialExtractor-TemporalEncoder-Integration-Classifier (STIC), which take the advantage of deep CNN and gated RNN to effectively extract and integrate the diagnosis-related radiological and clinical features of patients. The code is publicly available at https://github.com/ruitian-olivia/STIC-model. Results The STIC model achieved an accuracy of 86.2% and AUC of 0.893 for classifying HCC and ICC on the test set. When extended to differential diagnosis of malignant hepatic tumors, the STIC model achieved an accuracy of 72.6% on the test set, comparable with the diagnostic level of doctors’ consensus (70.8%). With the assistance of the STIC model, doctors achieved better performance than doctors’ consensus diagnosis, with an increase of 8.3% in accuracy and 26.9% in sensitivity for ICC diagnosis on average. On the external test set from center 2, the STIC model achieved an accuracy of 82.9%, which verify the model’s generalization ability. Conclusions We incorporated deep CNN and gated RNN in the STIC model design for differentiating malignant hepatic tumors based on multi-phase CECT and clinical features. Our model can assist doctors to achieve better diagnostic performance, which is expected to serve as an AI assistance system and promote the precise treatment of liver cancer. Supplementary Information The online version contains supplementary material available at 10.1186/s13045-021-01167-2.
Collapse
Affiliation(s)
- Ruitian Gao
- Department of Bioinformatics and Biostatistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China.,SJTU-Yale Joint Center for Biostatistics and Data Science, Shanghai Jiao Tong University, Shanghai, 200240, China
| | - Shuai Zhao
- Department of Transplantation, Xinhua Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China
| | - Kedeerya Aishanjiang
- Department of Transplantation, Xinhua Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China
| | - Hao Cai
- Department of Transplantation, Xinhua Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China
| | - Ting Wei
- Department of Bioinformatics and Biostatistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China.,SJTU-Yale Joint Center for Biostatistics and Data Science, Shanghai Jiao Tong University, Shanghai, 200240, China
| | - Yichi Zhang
- Department of Transplantation, Xinhua Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China
| | - Zhikun Liu
- Department of Hepatobiliary and Pancreatic Surgery, The Center for Integrated Oncology and Precision Medicine, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, China
| | - Jie Zhou
- Department of Bioinformatics and Biostatistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China.,SJTU-Yale Joint Center for Biostatistics and Data Science, Shanghai Jiao Tong University, Shanghai, 200240, China
| | - Bing Han
- Department of Transplantation, Xinhua Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China
| | - Jian Wang
- Department of Transplantation, Xinhua Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China
| | - Han Ding
- Department of Transplantation, Xinhua Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China
| | - Yingbin Liu
- Department of Biliary-Pancreatic Surgery, Renji Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China.
| | - Xiao Xu
- Department of Hepatobiliary and Pancreatic Surgery, The Center for Integrated Oncology and Precision Medicine, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, China.
| | - Zhangsheng Yu
- Department of Bioinformatics and Biostatistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China. .,SJTU-Yale Joint Center for Biostatistics and Data Science, Shanghai Jiao Tong University, Shanghai, 200240, China. .,Clinical Research Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
| | - Jinyang Gu
- Department of Transplantation, Xinhua Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
| |
Collapse
|
21
|
Wang S, Liu X, Zhao J, Liu Y, Liu S, Liu Y, Zhao J. Computer auxiliary diagnosis technique of detecting cholangiocarcinoma based on medical imaging: A review. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE 2021; 208:106265. [PMID: 34311415 DOI: 10.1016/j.cmpb.2021.106265] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/20/2021] [Accepted: 06/28/2021] [Indexed: 06/13/2023]
Abstract
BACKGROUND AND OBJECTIVES Cholangiocarcinoma (CCA) is one of the most aggressive human malignant tumors and is becoming one of the main factors of death and disability globally. Specifically, 60% to 70% of CCA patients were diagnosed with local invasion or distant metastasis and lost the chance of radical operation. The overall median survival time was less than 12 months. As a non-invasive diagnostic technology, medical imaging consisting of computed tomography (CT) imaging, magnetic resonance imaging (MRI), and ultrasound (US) imaging, is the most effectively and commonly used method to detect CCA. The computer auxiliary diagnosis (CAD) system based on medical imaging is helpful for rapid diagnosis and provides credible "second opinion" for specialists. The purpose of this review is to categorize and review the CAD technique of detecting CCA based on medical imaging. METHODS This work applies a four-level screening process to choose suitable publications. 125 research papers published in different academic research databases were selected and analyzed according to specific criteria. From the five steps of medical image acquisition, processing, analysis, understanding and verification of CAD combined with artificial intelligence algorithms, we obtain the most advanced insights related to CCA detection. RESULTS This work provides a comprehensive analysis and comparison analysis of the current CAD systems of detecting CCA. After careful investigation, we find that the main detection methods are traditional machine learning method and deep learning method. For the detection, the most commonly used method is semi-automatic segmentation algorithm combined with support vector machine classifier method, combination of which has good detection performance. The end-to-end training mode makes deep learning method more and more popular in CAD systems. However, due to the limited medical training data, the accuracy of deep learning method is unsatisfactory. CONCLUSIONS Based on analysis of artificial intelligence methods applied in CCA, this work is expected to be truly applied in clinical practice in the future to improve the level of clinical diagnosis and treatment of it. This work concludes by providing a prediction of future trends, which will be of great significance for researchers in the medical imaging of CCA and artificial intelligence.
Collapse
Affiliation(s)
- Shiyu Wang
- School of Electronic and Electric Engineering, Shanghai University of Engineering Science, Shanghai 201620, China
| | - Xiang Liu
- School of Electronic and Electric Engineering, Shanghai University of Engineering Science, Shanghai 201620, China.
| | - Jingwen Zhao
- School of Electronic and Electric Engineering, Shanghai University of Engineering Science, Shanghai 201620, China
| | - Yiwen Liu
- School of Electronic and Electric Engineering, Shanghai University of Engineering Science, Shanghai 201620, China
| | - Shuhong Liu
- Department of Pathology and Hepatology, The Fifth Medical Centre of Chinese PLA General Hospital, Beijing 100039, China
| | - Yisi Liu
- Department of Pathology and Hepatology, The Fifth Medical Centre of Chinese PLA General Hospital, Beijing 100039, China
| | - Jingmin Zhao
- Department of Pathology and Hepatology, The Fifth Medical Centre of Chinese PLA General Hospital, Beijing 100039, China.
| |
Collapse
|
22
|
Feng B, Ma XH, Wang S, Cai W, Liu XB, Zhao XM. Application of artificial intelligence in preoperative imaging of hepatocellular carcinoma: Current status and future perspectives. World J Gastroenterol 2021; 27:5341-5350. [PMID: 34539136 PMCID: PMC8409162 DOI: 10.3748/wjg.v27.i32.5341] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/28/2021] [Revised: 04/15/2021] [Accepted: 07/27/2021] [Indexed: 02/06/2023] Open
Abstract
Hepatocellular carcinoma (HCC) is the most common primary malignant liver tumor in China. Preoperative diagnosis of HCC is challenging because of atypical imaging manifestations and the diversity of focal liver lesions. Artificial intelligence (AI), such as machine learning (ML) and deep learning, has recently gained attention for its capability to reveal quantitative information on images. Currently, AI is used throughout the entire radiomics process and plays a critical role in multiple fields of medicine. This review summarizes the applications of AI in various aspects of preoperative imaging of HCC, including segmentation, differential diagnosis, prediction of histopathology, early detection of recurrence after curative treatment, and evaluation of treatment response. We also review the limitations of previous studies and discuss future directions for diagnostic imaging of HCC.
Collapse
Affiliation(s)
- Bing Feng
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Xiao-Hong Ma
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Shuang Wang
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Wei Cai
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Xia-Bi Liu
- Beijing Laboratory of Intelligent Information Technology, School of Computer Science and Technology, Beijing Institute of Technology, Beijing 100081, China
| | - Xin-Ming Zhao
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| |
Collapse
|
23
|
Sato M, Tateishi R, Yatomi Y, Koike K. Artificial intelligence in the diagnosis and management of hepatocellular carcinoma. J Gastroenterol Hepatol 2021; 36:551-560. [PMID: 33709610 DOI: 10.1111/jgh.15413] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/03/2020] [Revised: 01/07/2021] [Accepted: 01/15/2021] [Indexed: 02/06/2023]
Abstract
Despite recent improvements in therapeutic interventions, hepatocellular carcinoma is still associated with a poor prognosis in patients with an advanced disease at diagnosis. Recently, significant progress has been made in image recognition through advances in the field of artificial intelligence (AI) (or machine learning), especially deep learning. AI is a multidisciplinary field that draws on the fields of computer science and mathematics for developing and implementing computer algorithms capable of maximizing the predictive accuracy from static or dynamic data sources using analytic or probabilistic models. Because of the multifactorial and complex nature of liver diseases, the machine learning approach to integrate multiple factors would appear to be an advantageous approach to improve the likelihood of making a precise diagnosis and predicting the response of treatment and prognosis of liver diseases. In this review, we attempted to summarize the potential use of AI in the diagnosis and management of liver diseases, especially hepatocellular carcinoma.
Collapse
Affiliation(s)
- Masaya Sato
- Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.,Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Ryosuke Tateishi
- Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Yutaka Yatomi
- Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Kazuhiko Koike
- Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| |
Collapse
|